Biotech · Private company
Pharming Technologies B.V.
Track this companyFree. Adds Pharming Technologies B.V. to your Dealase workspace and tells you when its record changes.
Clinical trials115 recruiting or active
Pipeline programs9From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline9
- CDZ173Phase 3 · Activated PI3Kdelta Syndrome (APDS); PASLI DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- LeniolisibPhase 3 · APDSClinicalTrials.gov · fetched Nov 12, 2026
- KL1333Phase 2 · Primary Mitochondrial DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- LeniolisibPhase 2 · PIDs Linked to PI3KClinicalTrials.gov · fetched Nov 12, 2026
- LeniolisibPhase 2 · Common Variable Immunodeficiency (CVID)ClinicalTrials.gov · fetched Nov 12, 2026
- LeniolisibPhase 2 · Primary Immunodeficiency Disorders (PIDs)ClinicalTrials.gov · fetched Nov 12, 2026
- NapazimonePhase 2 · Mitochondrial DiseasesClinicalTrials.gov · fetched Nov 12, 2026
- rhC1INHPhase 2 · Hereditary AngioedemaClinicalTrials.gov · fetched Nov 12, 2026
- RuconestPhase 2 · Confirmed Coronavirus DiseaseClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials11
- Open Label Extension to Assess Long Term Safety and Efficacy of KL1333 in Patients With Primary Mitochondrial DiseasePHASE2 · RECRUITING · started Jun 12, 2026ClinicalTrials.gov NCT07514338 · fetched Nov 12, 2026
- Long-term Safety and Efficacy of Leniolisib in PIDs With Immune DysregulationPHASE2 · ACTIVE_NOT_RECRUITING · started Apr 29, 2025ClinicalTrials.gov NCT06990529 · fetched Nov 12, 2026
- Leniolisib for Immune Dysregulation in CVIDPHASE2 · COMPLETED · started Feb 12, 2025ClinicalTrials.gov NCT06897358 · fetched Nov 12, 2026
- Leniolisib for Immune Dysregulation in PIDsPHASE2 · COMPLETED · started Oct 21, 2024ClinicalTrials.gov NCT06549114 · fetched Nov 12, 2026
- Pediatric Patients Aged 1 to 6 Years With APDSPHASE3 · ACTIVE_NOT_RECRUITING · started Aug 30, 2023ClinicalTrials.gov NCT05693129 · fetched Nov 12, 2026
- Pediatric Patients Aged 4 to 11 Years With APDSPHASE3 · ACTIVE_NOT_RECRUITING · started Feb 1, 2023ClinicalTrials.gov NCT05438407 · fetched Nov 12, 2026
- Efficacy of KL1333 in Adult Patients With Primary Mitochondrial DiseasePHASE2 · RECRUITING · started Dec 13, 2022ClinicalTrials.gov NCT05650229 · fetched Nov 12, 2026
- Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19PHASE2 · COMPLETED · started Nov 30, 2020ClinicalTrials.gov NCT04530136 · fetched Nov 12, 2026
- Patient Registry to Evaluate the Real-world Safety of Ruconest®COMPLETED · started Jun 30, 2018ClinicalTrials.gov NCT03697187 · fetched Nov 12, 2026
- Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLIPHASE2_PHASE3 · TERMINATED · started Sep 8, 2016ClinicalTrials.gov NCT02859727 · fetched Nov 12, 2026
- Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) PatientsPHASE2 · COMPLETED · started Jan 17, 2012ClinicalTrials.gov NCT01359969 · fetched Nov 12, 2026